Skip to main content
Premium Trial:

Request an Annual Quote

Australia's Proteomics International Laboratories Launches A$6M IPO

NEW YORK(GenomeWeb) – Australian proteomics firm Proteomics International Laboratories today said it plans to offer up to A$6 million (US$5.2 million) of its shares in an initial public offering on the Australian Stock Exchange.

The firm said in a prospectus that it seeks to raise between A$4 million and A$6 million through an offering of up to 30 million shares of its stock at A$.20 per share. The proceeds will be used to drive growth in each of its three business units: analytical services, diagnostics, and therapeutics.

Founded in 2001, Perth-based PIL offers proteomics services including contract research, analytical testing, and consulting. The company also has a biomarker development program focused on diabetic kidney disease and Alzheimer's disease, as well as a therapeutics program focused on peptide drug discovery from venoms with a focus on painkillers and antibiotics.

Since its founding, PIL has generated gross revenues of A$7.5 million.

The company opened the stock offering on November 3 and plans to close it on November 28 in anticipation of a December 16 listing on the ASX.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.